Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

Next Previous
Search
Trial Profile

A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG 1050 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Transgene

    • Most Recent Events

    • 13 Nov 2018 Results of unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 12 Nov 2018 According to a Transgene media release,Prof. Fabien Zoulim, MD, PhD, is the principal investigator of the trial.
    • 12 Nov 2018 According to a Transgene media release,the company announced that the complete data from this study has been presented at the American Association for the Study of Liver Diseases (AASLD) 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top